Multivariate Biomarker Panel for Early MS Progression Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
MRI scans for monitoring multiple sclerosis (MS) disease progression are expensive and time-consuming, limiting nimble clinical management, while individual biomarkers often fail to detect subtle progression or differentiate MS from other neurologic conditions.
Innovation Solution
A multivariate biomarker panel analyzing the expression levels of multiple biomarkers, including CD1C, DLG4, TXNDC15, SOD2, and others, is used to predict MS disease progression through a predictive model, enhancing sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If MRI scans are used to monitor MS disease progression, then measurement precision is improved, but loss of time and cost increase
Solution Approach 1:
The patent replaces expensive, time-consuming MRI scans with a cheaper, faster blood-based biomarker panel assay. The biomarker panel provides a disposable, rapid alternative to repeated MRI imaging, enabling frequent monitoring without the time and cost burden of MRI while maintaining disease progression detection capability through multiple biomarker indicators.
Solution Approach 2:
The patent substitutes the mechanical imaging system (MRI) with a biochemical analysis system (biomarker panel). Instead of using magnetic fields and image processing to detect disease progression, the system uses blood draws and biomarker measurement, replacing a complex mechanical imaging process with a simpler biochemical assay that achieves comparable diagnostic information.
2Device complexity
If individual biomarkers are used to detect MS progression, then simplicity is improved, but measurement precision deteriorates due to false negatives
Solution Approach 1:
The patent combines multiple individual biomarkers into a unified biomarker panel that assesses disease progression through several markers simultaneously. By merging CD1C, DLG4, TXNDC15, SOD2, and other biomarker measurements into a single integrated panel, the system achieves higher measurement precision and reduces false negatives compared to any single biomarker alone, while maintaining relative simplicity through a single blood draw and comprehensive assay.
Solution Approach 2:
The patent creates a composite diagnostic tool by combining multiple biomarkers into a panel, analogous to creating composite materials for enhanced properties. The biomarker panel functions as a composite diagnostic system where the collective information from multiple biomarkers provides superior detection accuracy and reliability compared to individual biomarkers, capturing different aspects of disease pathology simultaneously.
3Ease of operation
If individual biomarkers are used, then ease of operation is improved, but reliability deteriorates due to inability to differentiate MS from other conditions
Solution Approach 1:
The patent merges multiple biomarkers with different specificities into a single panel that can differentiate MS from other neurologic conditions. The combination of biomarkers including CD1C, DLG4, TXNDC15, SOD2, and others creates a diagnostic profile that captures the unique pattern of MS pathology, enabling reliable differentiation from other conditions while maintaining ease of operation through a single comprehensive blood-based test.
Data Source
AI summary
Disclosed herein are methods for analyzing quantitative expression values of biomarkers of a biomarker panel for determining multiple sclerosis disease activity (e.g., multiple sclerosis disease progression) in a human subject. Further disclosed herein are kits for measuring quantitative expression values of the markers as well as computer systems and software embodiments of models for determining multiple sclerosis disease activity (e.g., multiple sclerosis disease progression) in human subjects based on the quantitative expression values of the markers.